Course Videos
How do the PK/PD dimensions of GLP-1-RAs determine their proper alignment with specific glycemic regulation needs (FPG vs PPG) and with specific clinical profiles of patients with T2D?
From a practical, clinical perspective what advantages are offered by the two fixed ratio combination formulations, i.e. glargine insulin plus lixisenatide vs. degludec insulin plus liraglutide that seem to be on their way to approval?
What is the role of incretin axis for lowering PPG?
What is the role of incretin axis for lowering PPG?
What degree of HA1c reductions can we expect to see with fixed ratio, basal insulin-GLP-1 RA combinations?
How will fixed ratio, basal insulin-GLP-1 RA combinations likely fit into the sequencing algorithm for diabetes care? How do we select among the available options? And in whom should we use these formulations?
What are the ideal clinical profiles for and distinctions among the fixed ratio, combination formulations? What are their potential advantages—i.e., reduced risk of weight gain and hypoglycemia —and unique therapeutic windows of opportunities?
What critical advances in the development of long-acting insulin and GLP-1 RA—and combination approaches using both—are having a positive impact on management of T2D? How should PK/PD properties affect our choice of specific GLP-1 RA? ...
What is the physiologic and clinical rationale for combining basal insulin and a GLP-1 RA as a treatment strategy for T2D?
What are the multi-factorial effects of GLP-1 RAs?
What are the multi-factorial effects of GLP-1 RAs?
What are the physiologic and clinical properties of incretin system-targeting agents?
What are the physiologic and clinical properties of incretin system-targeting agents?
Based on physiologic properties, which patients are eligible for short- vs long-acting GLP-1 RAs? And why is the combination of basal insulin and GLP-1 RA a reasonable strategy?